title: MNPs-Fe₃O₄mediates malignant Hematolpoectic cell apoptosis.
abstract: This study was purposed to evaluate whether the safe concentration of magnetic nanoparticles of Fe₃O₄(MNPs-Fe₃O₄) for monocytes could induce the SKM-1 cell apoptosis. The average size and Zeta potential of MNPs-Fe₃O₄were determined by transmission electron microscopy and the Malvern Zetasizer 3000 HS, respectively. The cell viability after being exposed to MNPs-Fe₃O₄for 12, 24, 48, and 72 hours was detected by using cell count Kit-8. The cell apoptosis was evaluated by flow cytometry with Annexin V/PI double staining and Wright-Giemsa staining. The cell cycle was measured by flow cytometry. The levels of active caspase-3, survivin and bcl-rambo in cells treated with MNPs-Fe₃O₄and/or trolox for 48 hours were detected with Western blot. The results showed that the cell viability decreased in SKM-1 cells after exposure to 50 µmol/L and 100 µmol/L MNPs-Fe₃O₄(P < 0.05), but did not in monocytes (P > 0.05), compared with that of each non-MNPs-Fe₃O₄-treated group. This exposure also induced the SKM-1 cells to be arrested in G0/G1. Annexin V/PI staining assay showed that cell apoptotic rate induced by 100 µmol/L MNPs-Fe₃O₄was significantly high in SKM-1 cells while not so high in monocytes, and the pretreatment with trolox could attenuate the apoptosis. Moreover, the active caspase-3 increased in SKM-1 cells after the exposure to MNPs-Fe₃O₄, while that was not in monocytes, and the increased expression of BCL-rambo and the decreased expression of survivin involved in the process were also observed. It is concluded that MNPs-Fe₃O₄can induce the caspase 3-dependent SKM-1 cell apoptosis by increasing the BCL-rambo expression and decreasing the survivin expression, but this cytotoxic effect can not be observed in monocyte's.
authors.affiliation: Hebei Provincial Blood Center, The Second Hospital of Hebei Medical University, Shijiazhuang 050000, Hebei Province, China.
authors.forename: Yu-Qiu
authors.initials: YQ
authors.lastname: Li
authors.affiliation: Hebei Provincial Blood Center, The Second Hospital of Hebei Medical University, Shijiazhuang 050000, Hebei Province, China.
authors.forename: Bing
authors.initials: B
authors.lastname: Wang
authors.affiliation: Hebei Provincial Blood Center, The Second Hospital of Hebei Medical University, Shijiazhuang 050000, Hebei Province, China.
authors.forename: Wen-Ce
authors.initials: WC
authors.lastname: Li
authors.affiliation: Hebei Provincial Blood Center, The Second Hospital of Hebei Medical University, Shijiazhuang 050000, Hebei Province, China.
authors.forename: Min
authors.initials: M
authors.lastname: Guo
authors.affiliation: Department of Hematology, The Second Hospital of Hebei Medical University, Shijiazhuang 050000, Hebei Province, China. E-mail: Wangying730@126.com.
authors.forename: Ying
authors.initials: Y
authors.lastname: Wang
authors.affiliation: Department of Hematology, The Second Hospital of Hebei Medical University, Shijiazhuang 050000, Hebei Province, China.
authors.forename: Yu-Jie
authors.initials: YJ
authors.lastname: Guo
authors.affiliation: Department of Hematology, The Second Hospital of Hebei Medical University, Shijiazhuang 050000, Hebei Province, China.
authors.forename: Fu-Xu
authors.initials: FX
authors.lastname: Wang
authors.affiliation: Department of Hematology, The Second Hospital of Hebei Medical University, Shijiazhuang 050000, Hebei Province, China.
authors.forename: Shu-Peng
authors.initials: SP
authors.lastname: Wen
authors.affiliation: Department of Hematology, The Second Hospital of Hebei Medical University, Shijiazhuang 050000, Hebei Province, China. E-mail: Lingpan20002000@aliyun.com.
authors.forename: Ling
authors.initials: L
authors.lastname: Pan
authors.affiliation: Department of Hematology, The Second Hospital of Hebei Medical University, Shijiazhuang 050000, Hebei Province, China.
authors.forename: Xue-Jun
authors.initials: XJ
authors.lastname: Zhang
mesh_terms: D017209:Apoptosis / Q000187:drug effects*; D053148:Caspase 3; D002453:Cell Cycle; D045744:Cell Line, Tumor; D005290:Ferric Compounds / Q000494:pharmacology*; D005434:Flow Cytometry; D006801:Humans; D008280:Magnetics; D053768:Metal Nanoparticles / Q000008:administration & dosage*
chemical_list: D005290:Ferric Compounds; C000499:ferric oxide; D053148:Caspase 3